NEW ORLEANS — In this video, Samer Al Hadidi, MD, MS, FACP, discusses an analysis of access to chimeric antigen receptor T-cell therapy presented at the ASH Annual Meeting and Exposition.
“Patients in the real world continue to show responses to this product, but the problem we have in the real world is the availability of those products for patients who need it,” Al Hadidi, University of Arkansas for Medical Sciences, said.
In an analysis of clinical outcomes of patients with relapsed refractory multiple myeloma listed to receive CAR-T, Al Hadidi and colleagues found a low cumulative
